Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
14 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
14
Trials led
0
Ongoing
4,796
Total enrollment
933
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 3
14
Trials by status
Completed
11
Terminated
3
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Terminated1,197
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Completed601
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Completed522
A Phase 3, 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of 2 Fixed Doses of Brexpiprazole in the Treatment of Alzheimer's AgitationAlzheimer's diseasePh 3Completed433
Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Completed387
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Completed345
Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Completed270
A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's TypeStudy partner/caregiver requiredPh 3Completed259
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Terminated241
Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's TypeAlzheimer's diseasePh 3Completed232
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's TypeAlzheimer's diseasePh 3Terminated184
Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With DementiaAlzheimer's diseasePh 3Completed125
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeAge 55-95Ph 3Completednot disclosed
Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's TypeAge 55-95Ph 3Completednot disclosed